ESPERION THERAPEUTICS INC. - COMMON STOCK

Esperion to Report Third Quarter 2025 Financial Results on November 6

23 окт 2025 08:00:00 Источник Nasdaq GlobeNewswire

Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis

16 окт 2025 08:00:00 Источник Nasdaq GlobeNewswire

Esperion Announces Pricing of Public Offering of Common Stock

07 окт 2025 21:29:06 Источник Nasdaq GlobeNewswire

Esperion Announces Proposed Public Offering of Common Stock

07 окт 2025 16:01:59 Источник Nasdaq GlobeNewswire

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

03 окт 2025 08:00:00 Источник Nasdaq GlobeNewswire

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

19 сен 2025 08:00:00 Источник Nasdaq GlobeNewswire

Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

29 авг 2025 08:00:00 Источник Nasdaq GlobeNewswire

Esperion to Participate in Upcoming September Investor Conferences

26 авг 2025 08:00:01 Источник Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

07 авг 2025 17:30:00 Источник Nasdaq GlobeNewswire

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

05 авг 2025 06:00:00 Источник Nasdaq GlobeNewswire

Esperion to Report Second Quarter 2025 Financial Results on August 5

22 июл 2025 08:00:00 Источник Nasdaq GlobeNewswire

Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

08 июл 2025 08:00:01 Источник Nasdaq GlobeNewswire

Esperion Appoints Craig Thompson to Board of Directors

01 июл 2025 08:06:21 Источник Nasdaq GlobeNewswire

Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

02 июн 2025 08:00:00 Источник Nasdaq GlobeNewswire

Esperion to Participate in Upcoming June Investor Conferences

20 май 2025 08:00:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months Low: ESPERION THERAPEUTICS INC. - COMMON STOCK

15 май 2025 09:49:04 Источник NetDania Notify

NetDania - New 12 months Low: ESPERION THERAPEUTICS INC. - COMMON STOCK

14 май 2025 10:46:17 Источник NetDania Notify

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

12 май 2025 08:00:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months Low: ESPERION THERAPEUTICS INC. - COMMON STOCK

09 май 2025 11:42:13 Источник NetDania Notify

Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference

09 май 2025 08:00:01 Источник Nasdaq GlobeNewswire